These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 32420142)
41. The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis. Li P; Zhong Y; Zhang M; Zheng Y; Peng W Transl Cancer Res; 2024 Aug; 13(8):3944-3959. PubMed ID: 39262473 [TBL] [Abstract][Full Text] [Related]
42. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis. Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117 [TBL] [Abstract][Full Text] [Related]
43. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941 [TBL] [Abstract][Full Text] [Related]
44. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599 [TBL] [Abstract][Full Text] [Related]
45. Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis. Kim SI; Kim SJ; Kim SJ; Cho DS Urol Oncol; 2021 Oct; 39(10):623-630. PubMed ID: 34253447 [TBL] [Abstract][Full Text] [Related]
46. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
48. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis. Qin Y; Luan J; Zhou X; Li Y Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390 [TBL] [Abstract][Full Text] [Related]
49. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. Huang X; Zhang W; Zhang Z; Shi D; Wu F; Zhong B; Shao Z J Cancer; 2018; 9(14):2525-2531. PubMed ID: 30026851 [No Abstract] [Full Text] [Related]
50. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Liu X; Shan C; Song Y; Du J Front Oncol; 2019; 9():1111. PubMed ID: 31709181 [No Abstract] [Full Text] [Related]
51. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410 [TBL] [Abstract][Full Text] [Related]
52. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947 [TBL] [Abstract][Full Text] [Related]
53. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Zhang L; Wu B; Zha Z; Zhao H; Feng Y Cancer Manag Res; 2018; 10():1687-1703. PubMed ID: 29970967 [TBL] [Abstract][Full Text] [Related]
54. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis. Zhou ZY; Liu SR; Xu LB; Liu C; Zhang R J Clin Transl Hepatol; 2021 Dec; 9(6):889-897. PubMed ID: 34966652 [TBL] [Abstract][Full Text] [Related]
55. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. Shi T; Zhu S; Guo H; Li X; Zhao S; Wang Y; Lei X; Huang D; Peng L; Li Z; Xu S Front Oncol; 2021; 11():567978. PubMed ID: 33708622 [TBL] [Abstract][Full Text] [Related]
56. The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. Lu Y; Kang J; Luo Z; Song Y; Tian J; Li Z; Wang X; Liu L; Yang Y; Liu X Front Oncol; 2020; 10():1400. PubMed ID: 32974145 [No Abstract] [Full Text] [Related]
57. Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. Uemura M; Nakaigawa N; Sassa N; Tatsugami K; Harada K; Yamasaki T; Matsubara N; Yoshimoto T; Nakagawa Y; Fukuyama T; Oya M; Shinohara N; Uemura H; Tsuzuki T Int J Clin Oncol; 2021 Nov; 26(11):2073-2084. PubMed ID: 34291367 [TBL] [Abstract][Full Text] [Related]
58. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis. Xu J; Zhao J; Wang J; Sun C; Zhu X Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106 [TBL] [Abstract][Full Text] [Related]
59. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L Front Pharmacol; 2019; 10():139. PubMed ID: 30873025 [No Abstract] [Full Text] [Related]
60. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]